STOCK TITAN

[Form 4] Traws Pharma, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Traws Pharma, Inc. filed a Form 4 reporting a director stock option grant. On 10/12/2025, the reporting person received a stock option to purchase 11,530 shares of common stock at an exercise price of $3.01 per share.

The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following this grant, 11,530 derivative securities were beneficially owned on a direct basis. The filing lists no transactions in non-derivative common stock.

Traws Pharma, Inc. ha presentato un modulo Form 4 riferendo una concessione di opzione azionaria per un dirigente. Il 10/12/2025 la persona che segnala ha ricevuto un'opzione azionaria per acquistare 11.530 azioni ordinarie a un prezzo di esercizio di 3,01 $ per azione.

L'opzione vesti 100% il 10/12/2026 e scade il 10/12/2035. A seguito di questa concessione, 11.530 strumenti derivati erano detenuti direttamente dall'interessato. Il deposito non elenca transazioni su azioni ordinarie non derivate.

Traws Pharma, Inc. presentó un Formulario 4 reportando una concesión de opción sobre acciones para un director. El 12/10/2025, la persona que reporta recibió una opción para comprar 11.530 acciones comunes a un precio de ejercicio de 3,01 $ por acción.

La opción vence 100% el 12/10/2026 y expira el 12/10/2035. Después de esta concesión, 11.530 valores derivados fueron poseídos de forma beneficiosa de manera directa. El registro no lista transacciones en acciones comunes no derivadas.

Traws Pharma, Inc.은 이사 주식 매수선택권 부여에 대해 Form 4를 제출했습니다. 2025년 10월 12일, 보고인은 보통주 11,530주를 매수할 수 있는 스톡 옵션을 행사 가격 3.01달러로 받았습니다.

옵션은 2026년 10월 12일에 100% 취득되며 2035년 10월 12일에 만료됩니다. 이 부여 이후, 11,530개의 파생증권이 직접적으로 유리하게 보유되었습니다. 이 서류는 비파생 일반주식의 거래를 목록에 올리지 않습니다.

Traws Pharma, Inc. a déposé un formulaire Form 4 signalant l'octroi d'une option d'achat d'actions à un administrateur. Le 12/10/2025, la personne déclarant a reçu une option d'achat pour acquérir 11 530 actions ordinaires à un prix d'exercice de 3,01 $ par action.

L'option acquiert 100 % des droits le 12/10/2026 et expire le 12/10/2035. Suite à cette attribution, 11 530 valeurs dérivées étaient détenues directement par le bénéficiaire. Le dépôt n'indique aucune transaction sur des actions ordinaires non dérivées.

Traws Pharma, Inc. hat ein Formular 4 eingereicht, das die Gewährung einer Aktienoptionszusage für einen Direktor meldet. Am 12.10.2025 erhielt die meldepflichtige Person eine Option zum Erwerb von 11.530 Stammaktien zu einem Ausübungspreis von 3,01 $ pro Aktie.

Die Option vestet 100% am 12.10.2026 und läuft am 12.10.2035 ab. Nach dieser Zuteilung waren 11.530 derivative Wertpapiere direkt im Eigentum des Meldenden. Die Einreichung listet keine Transaktionen in nicht-derivativen Stammaktien auf.

قدمت شركة Traws Pharma, Inc. نموذج Form 4 يفيد بمنح خيار شراء أسهم لمدير. في 12/10/2025 تلقى الشخص المبلّغ خيار شراء 11,530 سهماً من الأسهم العادية بسعر ممارسة 3,01 دولار للسهم.

يستحق الخيار الإكمال بنسبة 100% في 12/10/2026 وينتهي في 12/10/2035. بعد هذه المنحة، كانت 11,530 أداة مشتقة مملوكة بشكل مباشر للمستفيد. لا يذكر الملف أية معاملات في الأسهم العادية غير المشتقة.

Traws Pharma, Inc. 已提交4表格,报告董事股票期权授予。 在 2025/10/12,报告人收到一份购买11,530股普通股的股票期权,行使价格为每股3.01美元。

该期权于 2026/10/12 全部归属,于 2035/10/12 到期。此授予之后,11,530份衍生证券直接由受益所有人持有。该备案未列出非衍生普通股的任何交易。

Positive
  • None.
Negative
  • None.

Traws Pharma, Inc. ha presentato un modulo Form 4 riferendo una concessione di opzione azionaria per un dirigente. Il 10/12/2025 la persona che segnala ha ricevuto un'opzione azionaria per acquistare 11.530 azioni ordinarie a un prezzo di esercizio di 3,01 $ per azione.

L'opzione vesti 100% il 10/12/2026 e scade il 10/12/2035. A seguito di questa concessione, 11.530 strumenti derivati erano detenuti direttamente dall'interessato. Il deposito non elenca transazioni su azioni ordinarie non derivate.

Traws Pharma, Inc. presentó un Formulario 4 reportando una concesión de opción sobre acciones para un director. El 12/10/2025, la persona que reporta recibió una opción para comprar 11.530 acciones comunes a un precio de ejercicio de 3,01 $ por acción.

La opción vence 100% el 12/10/2026 y expira el 12/10/2035. Después de esta concesión, 11.530 valores derivados fueron poseídos de forma beneficiosa de manera directa. El registro no lista transacciones en acciones comunes no derivadas.

Traws Pharma, Inc.은 이사 주식 매수선택권 부여에 대해 Form 4를 제출했습니다. 2025년 10월 12일, 보고인은 보통주 11,530주를 매수할 수 있는 스톡 옵션을 행사 가격 3.01달러로 받았습니다.

옵션은 2026년 10월 12일에 100% 취득되며 2035년 10월 12일에 만료됩니다. 이 부여 이후, 11,530개의 파생증권이 직접적으로 유리하게 보유되었습니다. 이 서류는 비파생 일반주식의 거래를 목록에 올리지 않습니다.

Traws Pharma, Inc. a déposé un formulaire Form 4 signalant l'octroi d'une option d'achat d'actions à un administrateur. Le 12/10/2025, la personne déclarant a reçu une option d'achat pour acquérir 11 530 actions ordinaires à un prix d'exercice de 3,01 $ par action.

L'option acquiert 100 % des droits le 12/10/2026 et expire le 12/10/2035. Suite à cette attribution, 11 530 valeurs dérivées étaient détenues directement par le bénéficiaire. Le dépôt n'indique aucune transaction sur des actions ordinaires non dérivées.

Traws Pharma, Inc. hat ein Formular 4 eingereicht, das die Gewährung einer Aktienoptionszusage für einen Direktor meldet. Am 12.10.2025 erhielt die meldepflichtige Person eine Option zum Erwerb von 11.530 Stammaktien zu einem Ausübungspreis von 3,01 $ pro Aktie.

Die Option vestet 100% am 12.10.2026 und läuft am 12.10.2035 ab. Nach dieser Zuteilung waren 11.530 derivative Wertpapiere direkt im Eigentum des Meldenden. Die Einreichung listet keine Transaktionen in nicht-derivativen Stammaktien auf.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Clarke Trafford

(Last) (First) (Middle)
C/O TRAWS PHARMA, INC.
12 PENNS TRAIL

(Street)
NEWTOWN PA 18940

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to purchase) $3.01 10/12/2025 A 11,530 10/12/2026(1) 10/12/2035 Common Stock 11,530 $0 11,530 D
Explanation of Responses:
1. The options vest 100% on the first anniversary of the grant date.
/s/ Trafford Clarke 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Traws Pharma

NASDAQ:TRAW

TRAW Rankings

TRAW Latest News

TRAW Latest SEC Filings

TRAW Stock Data

20.17M
5.48M
14.86%
17.89%
1.45%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEWTOWN